Blueprint Medicines: Q1 Earnings Snapshot
Blueprint Medicines: Q4 Earnings Snapshot
Shares of Blueprint Medicines BPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to...
Ariel Hurley, the PRINCIPAL ACCOUNTING OFFICER of $BPMC ($BPMC), sold 1,200 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Christina Rossi, the CHIEF OPERATING OFFICER of $BPMC ($BPMC), sold 2,274 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.1%...
Blueprint Medicines: Q3 Earnings Snapshot
For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...
It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...
Blueprint Medicines: Q2 Earnings Snapshot
Blueprint Medicines: Q1 Earnings Snapshot